Impact News +++ Cadence Bank signals accelerated integration and targets continued margin improvement through 2025 (SeekingAlpha) +++ CADENCE BANK Aktie -3,73%

EDITAS Aktie

>EDITAS Aktienkurs

3.482 EUR -2.0% (Tradegate)

Ask: 3.474 EUR / 2880 Stück

Bid: 3.446 EUR / 2910 Stück

Tagesumsatz: 12270 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

EDITAS Aktie über LYNX handeln

Intraday

1 Jahr

>EDITAS Performance

1 Woche: +18,6%

1 Monat: +47,9%

3 Monate: +53,8%

6 Monate: +221,2%

1 Jahr: +17,1%

laufendes Jahr: +188,9%

>EDITAS Aktie

Name:

EDITAS MEDICINE DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US28106W1036 / A2AC4K

Symbol/ Ticker:

8EM (Frankfurt) / EDIT (NASDAQ)

Kürzel:

FRA:8EM, ETR:8EM, 8EM:GR, NASDAQ:EDIT

Index:

Webseite:

https://www.editasmedicin..

Profil:

Editas Medicine Inc. is a pioneering biotechnology..
>Volltext..

Marktkapitalisierung:

320.42 Mio. EUR

Unternehmenswert:

234.76 Mio. EUR

Umsatz:

33.48 Mio. EUR

EBITDA:

-132.61 Mio. EUR

Nettogewinn:

-203.87 Mio. EUR

Gewinn je Aktie:

-2.45 EUR

Schulden:

66.97 Mio. EUR

Liquide Mittel:

119.25 Mio. EUR

Operativer Cashflow:

-173.32 Mio. EUR

Bargeldquote:

2.71

Umsatzwachstum:

-47.23%

Gewinnwachstum:

-11.33%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

EDITAS

Letzte Datenerhebung:

21.10.25

>EDITAS Kennzahlen

Aktien/ Unternehmen:

Aktien: 89.92 Mio. St.

Frei handelbar: 99.1%

Leerverk. Aktien: 8.29%

Rückkaufquote: -17.29%

Mitarbeiter: 246

Umsatz/Mitarb.: 0.11 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: -2.89%

Bewertung:

KGV: -

KGV lG: -

KUV: 8.36

KBV: 18.87

PEG-Ratio: -0.06

EV/EBITDA: -

Rentabilität:

Bruttomarge: 82.7%

Gewinnmarge: -608.88%

Operative Marge: -413.35%

Managementeffizenz:

Gesamtkaprendite: -79.57%

Eigenkaprendite: -188.58%

>EDITAS Peer Group

Es sind 599 Aktien bekannt.

>EDITAS Chart & Kurs - NASDAQ

>EDITAS News

21.10.25 - 17:18	Gen-Editierung im Fokus: Editas Medicine präsentiert Strategie auf Chardan-Konferenz (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

09.10.25 - 17:03	Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress (GlobeNewswire EN)
	Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models...

06.10.25 - 15:03	Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences (GlobeNewswire EN)
	CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain....

11.09.25 - 19:00	Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report? (Zacks)
	Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

04.09.25 - 23:01	Insiderhandel: CEO verkauft Aktien von Editas Medicine im Wert von 14517 USD (Insiderkauf)
	O'neill, Gilmore Neil - Vorstand - Tag der Transaktion: 2025-09-03...

04.09.25 - 23:01	Insiderhandel: SVP, Chief Financial Officer verkauft Aktien von Editas Medicine im Wert von 1189 USD (Insiderkauf)
	Parison, Amy - Vorstand - Tag der Transaktion: 2025-09-03...

04.09.25 - 23:01	Insiderhandel: EVP, CHIEF SCIENTIFIC OFFICER verkauft Aktien von Editas Medicine im Wert von 1843 USD (Insiderkauf)
	Burkly, Linda - Vorstand - Tag der Transaktion: 2025-09-03...

03.09.25 - 17:31	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
	EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol....

02.09.25 - 13:03	Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate (GlobeNewswire EN)
	EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates...

28.08.25 - 22:03	Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate (GlobeNewswire EN)
	CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate....

27.08.25 - 15:03	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September:...

15.08.25 - 14:24	Why Editas Medicine Stock Was Skyrocketing This Week (Fool)
	The company's CEO made quite the encouraging statement regarding its immediate future....

13.08.25 - 01:00	Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
	Editas (EDIT) delivered earnings and revenue surprises of -53.66% and +320.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.08.25 - 22:06	Editas Medicine Announces Second Quarter 2025 Results and Business Updates (GlobeNewswire EN)
	Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026...

08.08.25 - 23:01	Insiderhandel: SVP, Chief Financial Officer verkauft Aktien von Editas Medicine im Wert von 1752 USD (Insiderkauf)
	Parison, Amy - Vorstand - Tag der Transaktion: 2025-08-07...

05.08.25 - 00:01	Insiderhandel: EVP, CHIEF SCIENTIFIC OFFICER verkauft Aktien von Editas Medicine im Wert von 12757 USD (Insiderkauf)
	Burkly, Linda - Vorstand - Tag der Transaktion: 2025-07-31...

28.06.25 - 11:36	Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

17.06.25 - 16:36	Editas Medicine Is Great. Here′s Why You Shouldn′t Buy It. (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

12.06.25 - 08:03	Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June (GlobeNewswire EN)
	Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy....

11.06.25 - 19:00	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
	Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ein gelegtes Ei kann zum Findling werden. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram